课题基金 / 基金详情

A novel urinary marker for detection of urothelial carcinoma The clinical significance and the biological role of 80KDa glycoprotein

A novel urinary marker for detection of urothelial carcinoma The clinical significance and the biological role of 80KDa glycoprotein
一种检测尿路上皮癌的新型尿液标记物 80KDa 糖蛋白的临床意义和生物学作用
批准号:
23592341
负责人:
KIMURA Taichi
金额:
$3.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2011
资助国家:
日本
项目状态:
已结题
起止时间:
2011 至 2013

项目摘要

项目成果

KIMURA Taichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Western blot analysis was performed using urine of the patients with bladder cancer (about 100 cases) by using the antibody reacts to the 80KDa glycoprotein (we detected previously). The result was revealed that these expression levels of 80KDa glycoprotein were higher in the advanced pathological grade cases statistifically significance.The real-time PCR revealed that mRNA level of 80KDa glycoprotein was higher in the order of normal urothelial cell line, low-grade urothelial cancer cell line and high-grade urothelial cancer cell lines.Treatment with histone deacetylase inhibitor and DNA methylation inhibitor restored LTF expression in utohelial cancer cell lines. Immunoreactivity of the 80KDa glycoprotein was undistinguished between cancer cells and normal urothelial cells in radical cystectomy specimens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heterogeneous Beliefs and Management Control System
  • 批准号:
    16H07173
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
  • 资助金额:
    $1.0万
  • 财政年份:
    2016
  • 负责人:
    KIMURA Taichi
  • 依托单位:
Identification of synovial sarcoma initiating cells
  • 批准号:
    23791621
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
  • 资助金额:
    $2.58万
  • 财政年份:
    2011
  • 负责人:
    KIMURA Taichi
  • 依托单位:
Identification of synovial sarcoma stem cell as a new therapeutic target
  • 批准号:
    21791383
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
  • 资助金额:
    $2.41万
  • 财政年份:
    2009
  • 负责人:
    KIMURA Taichi
  • 依托单位:
国内基金
海外基金
AKR1C1抑制铁死亡途径调节膀胱尿路上皮癌中维迪西妥单抗治疗的敏感性研究
  • 批准号:
    2026JJ81335
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    王晶晶
  • 依托单位:
冷冻消融介导肿瘤相关巨噬细胞代谢重编程强化上尿路尿路上皮癌免疫治疗敏感性的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    陈艺凌
  • 依托单位:
恶性肿瘤精准诊治新技术和新策略研究-新型基于Nectin-4靶点CAR-NK细胞疗法的开发及其治疗晚期尿路上皮癌的应用研究
TGFB1诱导CAFs细胞分化通过T细胞耗竭导致尿路上皮癌不良预后的机制研究
  • 批准号:
    JCZRLH202501210
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: